Next Treatments
Back to Eczema

zabedosertib

TypePill StagePhase 2 Latest updateFeb 18, 2025Phase 2 results posted

What stands out

  • Serine/threonine kinase inhibitor
Derived from WHO name stem · This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: Damask
Clear or almost clear skinAfter 12 weeks
Placebo22 people
29 in 100
Zabedosertib (BAY1834845)47 people
16 in 100
02040
13
fewer people in 100 reached it on zabedosertib than on placebo.
The sponsor’s 95% confidence range is 34 fewer to 7 more (out of 100).
Eczema score (EASI) at least 75% betterAfter 12 weeks
Placebo22 people
37 in 100
Zabedosertib (BAY1834845)47 people
32 in 100
02040
5
fewer people in 100 reached it on zabedosertib than on placebo.
The sponsor’s 95% confidence range is 29 fewer to 18 more (out of 100).
Eczema score (EASI) at least 90% betterAfter 12 weeks
Placebo22 people
20 in 100
Zabedosertib (BAY1834845)47 people
16 in 100
02040
5
fewer people in 100 reached it on zabedosertib than on placebo.
The sponsor’s 95% confidence range is 26 fewer to 13 more (out of 100).
NCT05656911 · Ages 18–65 · Results posted Feb 2025 · This is a summary of trial data for informational purposes only. It is not medical advice.
Trial: Damask
Itch score at least 4 points betterAfter 12 weeks
Placebo22 people
25 in 100
Zabedosertib (BAY1834845)47 people
16 in 100
02040
8
fewer people in 100 reached it on zabedosertib than on placebo.
The sponsor’s 95% confidence range is 30 fewer to 11 more (out of 100).
NCT05656911 · Ages 18–65 · Results posted Feb 2025 · This is a summary of trial data for informational purposes only. It is not medical advice.
What is IGA?
  • IGA stands for Investigator Global Assessment.
  • vIGA-AD stands for validated Investigator Global Assessment for Atopic Dermatitis. The vIGA-AD is a 1-item static ClinRO using a 5-point scale from 0 (clear) to 4 (severe) based on 4 clinical features of AD lesions: erythema, induration/papulation, lichenification, and oozing/crusting, and takes extent of disease into account. The main estimand was calculated similarly as for EASI 75.As this trial registered it · NCT05656911 (the full definition is there)
What is EASI?
  • EASI stands for Eczema Area and Severity Index.
  • The endpoint was the composite variable defined as follows: - an EASI 75 response at Week 12 (Day 84), - no stop of study intervention for reasons related to lack of efficacy, - no rescue medication use during the 4 weeks before Day 84 and - no use of systemic atopic dermatitis (AD) treatment.As this trial registered it · NCT05656911 (the full definition is there)
What is the itch score?
  • NRS stands for numerical rating scale.
  • NRS stands for numerical rating scale. The Peak Pruritus 0-10 NRS is a single patient-reported item designed to measure peak pruritus (itch), or 'worst' itch, over the previous 24 h based on the following question: 'On a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable", how would you rate your itch at the worst moment during the previous 24 hours?'.As this trial registered it · NCT05656911 (the full definition is there)
Why this trial?

zabedosertib has one trial with posted results, and Damask compared the drug with placebo on a result this page charts.

History

Earliest recorded event: Dec 21, 2022. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Feb 18, 2025Phase 2 results postedA Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05656911
  • Jan 31, 2024Phase 2 trial completedA Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05656911
  • Jan 3, 2024Phase 2 main data collectedA Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05656911
  • Dec 21, 2022Phase 2 trial startedA Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT05656911

Sources

Trials